Brisbane, Australia, 5 June 2019 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has appointed Naomi Fried, PhD and Joseph C. Kvedar, MD to its newly established Industry Advisory Board. The Industry Advisory Board will provide ResApp with strategic counsel on the commercialisation of its diagnostic and management platform for respiratory disease.
Dr Fried, a national thought leader on healthcare innovation, is founder and CEO of Health Innovation Strategies. Dr Fried was previously Biogen’s first Vice President of Innovation and External Partnerships. Prior to Biogen, she was the first Chief Innovation Officer at Boston Children’s Hospital (BCH) where she oversaw the FastTrack Innovation in Technology Program which developed novel clinical software solutions and mobile apps. She also initiated and led development of BCH’s telehealth strategy. Prior to BCH, Dr Fried was Vice President of Innovation and Advanced Technology in Kaiser Permanente’s (KP) Program Offices where she led an effort to identify and assess emerging health care technologies and formed KP’s Telehealth working group.
Dr Kvedar is recognised globally for leadership and vision in the field of digital health and has authored over 100 publications on the subject. He is currently Vice President, Connected Health at Partners HealthCare. Under Dr Kvedar’s two decades of leadership, Partners Connected Health has launched a number of innovative mobile health programs, virtual care initiatives and clinical research programs for the more than 1.5 million patients served at Partners HealthCare-affiliated hospitals. He is the author of The New Mobile Age: How Technology Will Extend the Healthspan and Optimize the Lifespan (2017) and The Internet of Healthy Things (2015).
Tony Keating, CEO and Managing Director of ResApp commented, “As we begin the global commercialisation of our products, we are excited to announce the formation of our Industry Advisory Board. Both Dr Fried and Dr Kvedar are incredibly talented and experienced professionals who are recognised leaders in digital health and bring a vast amount of experience from within the US healthcare system. We are confident that ResApp will benefit greatly from their insights, judgment and counsel.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in the United States and Australia have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a double-blind, prospective clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.